Amphastar Pharmaceuticals, Inc. (AMPH) Financial Statements
Amphastar Pharmaceuticals, Inc. (AMPH) reported trailing twelve-month revenue of $730.0M (up 1.0% year on year) and net income of $78.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $152.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AMPHAmphastar Pharmaceuticals, Inc.Follow AMPH — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- 14.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.21 | 0.25 | 0.26 | 0.24 | 0.29 | 0.32 | 0.35 | 0.44 | 0.50 | 0.64 | 0.73 | 0.72 | 0.73 | |
| Gross profit | 0.05 | 0.08 | 0.10 | 0.09 | 0.11 | 0.13 | 0.14 | 0.20 | 0.25 | 0.35 | 0.37 | 0.36 | 0.35 | |
| Research & development | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.09 | 0.09 | |
| Operating income | -0.02 | -0.01 | 0.02 | -0.00 | -0.01 | -0.00 | 0.01 | 0.07 | 0.11 | 0.20 | 0.21 | 0.14 | 0.11 | |
| Pre-tax income | -0.02 | -0.01 | 0.01 | 0.00 | -0.01 | 0.06 | 0.00 | 0.08 | 0.12 | 0.17 | 0.19 | 0.12 | 0.10 | |
| Income tax | -0.01 | -0.01 | 0.00 | -0.00 | -0.00 | 0.01 | 0.00 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Net income | -0.01 | -0.00 | 0.01 | 0.00 | -0.01 | 0.05 | 0.00 | 0.06 | 0.09 | 0.14 | 0.16 | 0.10 | 0.08 | |
| Diluted EPS ($) | -0.25 | -0.06 | 0.21 | 0.08 | -0.12 | 0.98 | 0.03 | 1.25 | 1.74 | 2.60 | 3.06 | 2.03 | 1.69 | |
| Diluted shares (bn) | 0.042 | 0.045 | 0.048 | 0.048 | 0.046 | 0.050 | 0.049 | 0.050 | 0.052 | 0.053 | 0.052 | 0.048 | — |
USD billions · SEC XBRL
Amphastar Pharmaceuticals, Inc. — questions
- What is Amphastar Pharmaceuticals, Inc.'s revenue?
- $730.0M over the twelve months to 2026-06-30, up 1.0% year on year, from its 10-Q and 10-K filings.
- What is Amphastar Pharmaceuticals, Inc.'s net income?
- $78.5M over the twelve months to 2026-06-30.
- What is Amphastar Pharmaceuticals, Inc.'s free cash flow?
- $152.9M over the twelve months to 2026-06-30.
- What are Amphastar Pharmaceuticals, Inc.'s diluted earnings per share?
- $1.69 over the twelve months to 2026-06-30.
Every figure on this page comes from Amphastar Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.